US2914528A - Substituted phenothiazinyl trifluoro-methyl sulfones - Google Patents

Substituted phenothiazinyl trifluoro-methyl sulfones Download PDF

Info

Publication number
US2914528A
US2914528A US728773A US72877358A US2914528A US 2914528 A US2914528 A US 2914528A US 728773 A US728773 A US 728773A US 72877358 A US72877358 A US 72877358A US 2914528 A US2914528 A US 2914528A
Authority
US
United States
Prior art keywords
trifluoromethylsulfonylphenothiazine
acid
hours
solution
extracted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US728773A
Inventor
Paul N Craig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
GlaxoSmithKline LLC
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BE568478D priority Critical patent/BE568478A/xx
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Priority to US728773A priority patent/US2914528A/en
Priority to GB17724/58A priority patent/GB851886A/en
Priority to GB2640/60A priority patent/GB851887A/en
Priority to DES58547A priority patent/DE1173099B/en
Priority to FR767619A priority patent/FR1245551A/en
Priority to US803090A priority patent/US2919272A/en
Application granted granted Critical
Publication of US2914528A publication Critical patent/US2914528A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients

Definitions

  • the compounds of this invention have utility asantiemetics, tranquilizers, calmatives, antihistamines, spasmolytics, antishock agents and potentiators of various central nervous system depressants, such as analgetics or anesthetics. Particularly important are the utilities of these compounds as antiemetics and tranquilizers.
  • these compounds have chemotherapeutic or antimicrobial activity, such as antileprosy, antitubercular, antibacterial and fungicidal activity.
  • they possess unusual fungicidal or antibacterial activity such as against Diplococcus pneumoniae Type I, Hemolytic streptococcus, Micrococcus pyogenes var. aureus, Klebsiella pneumoniae andCandida albicans.
  • certain of these compounds have utility. as intermediates, aswill be evident from the following disclosure.
  • the 10-substituted phenothiazinyl. trifluoromethyl sulfones, of this invention are represented by the general formula:
  • R R R and R represent hydrogen, ethyl
  • A represents a divalent, straight or branched alkylene chain containing 2 to 4 carbon atoms, advantageously propylene, separating the nitrogen atoms byat least 2. carbons;
  • This invention also includes salts of the above defined bases formed with nontoxic organic and inorganic acids; Such salts are easily prepared by methods known to the art.
  • the base is reacted with either the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly.
  • aqueous miscible solvent such as acetone or ethanol
  • organic salts are those withv maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesal'icylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric salicyclic, citric, gluconic, lactic, malic, mandelic, cinnamic citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as with the S-halotheophyllines, for example, 8-chlorotheophy1line and 8-bromotheophylline.
  • the SO CF group is preferably in the 2-position.
  • X represents chloro, bromo or iodo.
  • the method is carried out by heating the sulfonyldiphenyl sulfides of Formula 5 in the presence of an acid-binding agent present in at least an amount sufficient to neutralize the hydrohalic acid formed during the reaction.
  • acid-binding agents are the carbonates, such as sodium carbonate, sodium bicarbonate or preferably potassium carbonate.
  • the reaction is run in a suitable, non-reactive organic solvent in which the reactants are at least partially soluble.
  • exemplary are dioxane, dimethylaniline, diethylformamide, methylformarnide, dimethylforinamide or dimethylacetamide.
  • the solvent is dimethylformamide and other similar lower carbon amides.
  • sulfonyldiphenyl sulfidese are prepared by method analogous to those in the prior art, for instance as illustrated hereafter for the preparation of Z-trifluoromethylsulfonylphenothiazine: 1
  • 3-nitro-4-chlorophenyl trifluoromethyl sulfide is oxidized to the corresponding sulfone with chromic anhydride in sulfuric acid.
  • the 3-nitro-4-chlorophenyl trifiuoromethyl sulfone is condensed with obromothiophenol under alkaline conditions to give the diphenyl sulfide.
  • the 2-nitro group is reduced with stannous chloride-hydrochloric acid to give 2-bromo-2-amino-4-trifluoromethylsulfonyldiphenyl sulfide which is then further reacted as described above.
  • the selected phenothiazinyl trifluoromethyl sulfones of Formula 4 are condensed with a reactive tertiary aminoalkyl ester having the desired dialkylaminoalkyl group to form the desired IO-aminoalkylphenothiazinyl trifluoro-.
  • aminoalkyl ester containing the Any reactive tertiary desired moiety may be used, such as the halides, preferably bromide or chloride, or the sulfonic esters, preferably p-toluene sulfonate.
  • the reaction is preferably carried out at a temperature in the range of from about 30 C. to about C.
  • the condensation is carried out advantageously by refluxing the reactants in an inert aromatic solvent such as, preferably, benzene, toluene or xylene, in which at least one of the reactants must be soluble.
  • a suitable acid-binding agent is usually included, such as an alkali metal amide, preferably, sodium, potassium or lithium amide.
  • acid-binding agents are alkali metal hydride, preferably sodium hydride or alkali metal aryl or alkyl compounds, preferably phenyl or actyl sodium. If the acid addition salt of the reactive ester is used, a corresponding increase in acid-binding agent must be used.
  • the w.-piperazinylalkylphenothiazinyl trifluoromethyl. sulfones are prepared advantageously by alkylating a trifluoromethylsulfonylphenothiazine (Formula 4) with an w-haloalkylpiperazine with the free N-hydrogen of the piperazinyl moiety protected by, for example, a benzyl, carbobenzoxy, or acyl, preferably formyl group. The N- protective group is then removed, such as by mild hydrolysis. The resulting w-piperazinyl alkylphenothiazinylsulfone may then be further alkylated to form various modifications of the compounds of.
  • Such methods of alkylation are by a reactive ester such as an alkyl halide in the presence of an acid-binding agent in inert solution such as benzene or butanone, by reaction with an alkylene oxide such as ethylene oxide in alcohol or by reduction of a N-acyl compound such as reduction of the N-acyl analogue with a bimetallic hydride such as lithium aluminum hydride.
  • Another route to these compounds is by means of w-ester alkylphenothiazinyl trifluoromethyl sulfones which have a reactive end group on the lO-alkyl chain, for example, an w-tosylate or w-chloro end group, which can be reacted with various amines to form primary or secondary amines, for instance by refluxing the ester and amine in the presence of an acid binder for short periods.
  • w-ester alkylphenothiazinyl trifluoromethyl sulfones which have a reactive end group on the lO-alkyl chain, for example, an w-tosylate or w-chloro end group, which can be reacted with various amines to form primary or secondary amines, for instance by refluxing the ester and amine in the presence of an acid binder for short periods.
  • the isomers may be'separated for individual use by separation methods known to the art, such as fractional crystallization, for instance, of the d-tartrate salts of the lO-aminoalkylated trifluoromethylsulfonylphenothiazine derivatives.
  • separation methods known to the art, such as fractional crystallization, for instance, of the d-tartrate salts of the lO-aminoalkylated trifluoromethylsulfonylphenothiazine derivatives.
  • a synthesis starting with an optically active side chain may yield the desired opticalisomer.
  • Example 1 A solution of 8.0 g. of chromic anhydride, 8.0 g. of sulfuric acid and 25 ml. of water is mixed with 15.4 g. of
  • Example 4 A mixture of 16.5 g. of Z-trifluoromethylsulfonyh phenothiazine (made as in Example 1), 2.4 g. of sodamide and 10.5 g. of 1-(3-chloropropyl)-4-methylpiperazine in 200 ml. of xylene is stirred and refluxed for four hours. The reaction mixture is extracted with water and the separated xylene layer extracted portion-wise with dilute hydrochloric acid. The combined acid extracts are The mixture is stirred and re- 7 neutralized with ammonium hydroxide and the product taken up in benzene.
  • the solvent is distilled ofl in vacuo, leaving the residual -[3'-(N-formylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine as a viscous oil.
  • Example 6 A stirred suspension of 22.8 g. of 10-(3'-piperazinylpropyl) -2-trifluoromethylsulfonylphenothiazine (prepared as in Example 6), 8.9 g. of B-bromoethyl acetate and 3.6 g. of potassium carbonate in 200 m1. of toluene is refluxed for 16 hours; The cooled reaction mixture is treated with water and the separated organic layer extracted with dilute acid. The combined acid extract is neutralized, further extracted with benzene and upon evaporation of the solvent in vacuo, an oily residue is obtained which is purified by chromatography through alumina.
  • Example 8 A solution of 2.2 g. of l0-[3'-(N-acetoxyethylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine (prepared as in Example 7) in 50 ml. of l N hydrochloric acid is refluxed for a short time. The reaction mixture is neutralized with dilute sodium carbonate solution and extracted with benzene. Evaporation of the solvent gives 10-[3(N-B-hydroxyethylpiperazinyl)-propyl]-2-trifiuoromethylsulfonylphenothiazine as an oil.
  • Example 9 azinyl) -propyl]-2-trifluoromethylsulfonylphenothiazine.
  • Example 10 To a solution of 4.6 g. of l0-(3'-piperazinylpropyl)-2- trifiuoromethylsulfonylphenothiazine (made as in Example 6) in 150.0 g. of benzene, 1.8 g. of phenylacetyl chloride is added dropwise with swirling. The mixture, after standing overnight, is filtered to give crystals of 10-[3' (N phenylacetylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine hydrochloride.
  • Example 11 A suspension of 9.2 g. of 10-(3-piperazinylpropyl)-2- trifluoromethylsulfonylphenothiazine, 5.6 g. of 4-bromo- 4'-hydroxybutyl ether (prepared by carefully treating 4,4-dihydroxybutyl ether with one equivalent of hydrobromic acid) and 4.2 g. of potassium carbonate in 200 ml. of xylene is heated at reflux for 24 hours. After treating the reaction mixture with water, the separated organic layer is extracted with acid. The acidic extracts are made basic and extracted with benzene. Removal of the solvent from the dried extracts yields l0-[3-(N-hydroxybutoxybutylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine.
  • Example 13 A mixture of 9.2 g. of l0-(3-piperazinylpropyl)-2-trifiuoromethylsulfonylphenothiazine, 1.8 g. of crotyl chloride and 1.6 g. of potassium carbonate in ml. of aqueous ethanol is stirred and heated at reflux for six hours. The reaction mixture is worked up as outlined in Example 7 to give lO-[3-(N-crotylpiperazinyl)-propyl]2-trifiuoromethylsulfonylphenothiazine.
  • a solution of the free base (1.0 g.) in ethyl acetate is treated with a solution of mandelic acid in ethanol. Concentration and cooling of the resulting solution yields the dimandelate salt.
  • Example 23 A suspension of 9.1 g. of 10 (3-piperazinylpropyl)-2- tr'ifiuoromethylsulfonylphenothiazine (made as in Example 6), 0.8 g. of sodium amide and 3.3 g. of 2-bromo-ldimethylaminoethane in ml. of benzene is refluxed for six hours, With stirring. Treating the reaction mixture as in Example 20 gives the product, 10-[3-(N- 3-dimethylaminoethylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine.
  • Example 24 A stirred suspension of 9.1 g. of l0-(3'-piperazinylpropyl)-2-trifluoromethylsulfonylphenothiazine *(made as in Example 6), 3.4 g. of w-bromobutanol and 4.0 g. of potassium carbonate in 125 ml. of xylene is refluxed for six hours. Water is added to the reaction mixture and the separated xylene layer is extracted with dilute hydrochloric acid. The acid extracts are neutralized and extracted with benzene. The solvent is distilled in vacuo to give a residue of 10-[3'-(N-w-hydroxybutylpiperazinyl)- propyl] -2'-trifluoromethylsulfonylphenothiazine.
  • Example 25 A mixture of 10.8 g. of 10-(3'-hydroxypropyl)-2-trifiuoromethylsulfonylphenothiazine p toluenesulfonate (prepared as outlined in Example 18), 5.0 g. of N- hydroxyethoxyethylpiperazine and 4.2 g. of potassium carbonate in 150 ml. of ethanol is heated at reflux for six hours, with stirring. The reaction mixture is treated with water, evaporated in vacuo and extracted with ethyl acetate. Evaporation of the dried solvent yields the product, 10 [3' (N hydroxyethoxyethylpiperazinyl) propyl] 2-trifluoromethylsulfonylphenothiazine.

Description

SUBSTITUTED PHENOTHIAZINYL TRIFLUORO- METHYL SULFONES Paul N. Craig, Roslyn, Pa., assignor to Smith, Kline & French Laboratories, Philadelphia, Pa., a corporation of Pennsylvania N Drawing. Application April "16, 1958 Serial No. 728,773
10 Claims. (Cl. 260-243) This invention relates to new IO-aminoalkylphenothiazinyl trifluoromethyl sulfones of value as therapeutic agents. Further, this invention relates to novel phenothiazinyl trifiuoromethyl sulfone intermediates.
More specifically, the compounds of this invention have utility asantiemetics, tranquilizers, calmatives, antihistamines, spasmolytics, antishock agents and potentiators of various central nervous system depressants, such as analgetics or anesthetics. Particularly important are the utilities of these compounds as antiemetics and tranquilizers. In addition, these compounds have chemotherapeutic or antimicrobial activity, such as antileprosy, antitubercular, antibacterial and fungicidal activity. For example, they possess unusual fungicidal or antibacterial activity, such as against Diplococcus pneumoniae Type I, Hemolytic streptococcus, Micrococcus pyogenes var. aureus, Klebsiella pneumoniae andCandida albicans. Further, certain of these compounds have utility. as intermediates, aswill be evident from the following disclosure.
The 10-substituted phenothiazinyl. trifluoromethyl sulfones, of this invention are represented by the general formula:
FORMULA 1 2 when FORMULA 2 N NR7 5 6 when:
R R R and R represent hydrogen, ethyl; and
R represents hydrogen, alkyl, acyloxyalkylene such as alkanoyloxyalkylene or monocyclic aroyloxy-alkylene such as benzoyloxyalkylene, hydroxyalkylene, dialkylmethyl or ice 2- aminoalkylene, hydroxy alkyleneoxyalkylene, monocya clic aralkyl of from 7 tell) carbons such as cinnamyl and phenylalkyl, or acyl, such as alkanoyl, phenyl alkanoyl, monocyclic aroyl, carbobenzoxy or lower N-substituted carbamyl such as dialkyl carbamyl.
The preferred substituted piperazinyl moieties are N-hydrogen piperazinyl, N-alkylpiperazinyl, N-(w-hydroxyalkylene) piperazinyl, N- w-alkanoyloxyalkylene) piperazinyl, N-(w-monocyclic aroyloxy-alkylene)-piperazinyl, N-monocyclic aralkylpiperazinyl, N-alkanoylpiperazinyl, N,2,3,5,6-pentamethylpiperazinyl or N-(whydroxy-alkyleneoxy-alkylene) piperazinyl.
The SO CF group is preferably in the 2' position. The preferred compounds of this invention are represented by the following structural formula:
When:
A represents a divalent, straight or branched alkylene chain containing 2 to 4 carbon atoms, advantageously propylene, separating the nitrogen atoms byat least 2. carbons; and
Z represents dimethylamino, piperazinyl or N-substituted piperazinyl, specifically alkyl, alkanoyloxyalkylene, hydroxy-alkyleneoxy-alkylene or hydroxy alkylene piperazinyl. I
By the term alkyl or alkanoyl where used herein alone or in combination with other terms, aliphatic groups having not more than 6carbon atoms and preferably not more than 4 carbon atoms are indicated except where otherwise specified. When the term alkylene is used in connection with a carbon chain, this term rep resents aliphatic groups of from 2 to 6 carbon atoms, preferably 2 to 4 carbons except where otherwise speci fied.
This invention also includes salts of the above defined bases formed with nontoxic organic and inorganic acids; Such salts are easily prepared by methods known to the art. The base is reacted with either the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly. Exemplary of such organic salts are those withv maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesal'icylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric salicyclic, citric, gluconic, lactic, malic, mandelic, cinnamic citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as with the S-halotheophyllines, for example, 8-chlorotheophy1line and 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course these salts may also be prepared by' the classical method of double decomposition of appropriate salts which is well-known to the art.
The novel phenothiazinyl trifluoromethyl sulfones, which are unsubstituted in the lO-position, are used as intermediates to prepare the biologically active IO-aminoalkylphenothiazinyl trifluoromethyl sulfones described in Formula 1; While these unsubstituted phenothiazinyl trifluoromethyl sulfones have utility particularly as intermediates, as indicated, they have significant 'antifungal FORMULA 4 sole F,
The SO CF group is preferably in the 2-position.
The compounds of Formula 4 are prepared by cyclizing the sulfonyldiphenylsulfides represented by the following formula:
FORMULA 5 XNH; 3
when:
R; and R are different and selected from the group consisting of H and -SO CF preferably in the 4 or 4' positions; and
X represents chloro, bromo or iodo.
Preferably R is hydrogen, R is SO CF in the 4- position, and X is bromo or iodo.
The method is carried out by heating the sulfonyldiphenyl sulfides of Formula 5 in the presence of an acid-binding agent present in at least an amount sufficient to neutralize the hydrohalic acid formed during the reaction. Exemplary of such acid-binding agents are the carbonates, such as sodium carbonate, sodium bicarbonate or preferably potassium carbonate. The reaction is run in a suitable, non-reactive organic solvent in which the reactants are at least partially soluble. Exemplary are dioxane, dimethylaniline, diethylformamide, methylformarnide, dimethylforinamide or dimethylacetamide. Preferably, the solvent is dimethylformamide and other similar lower carbon amides.
Optimum yields are obtained when catalytic amounts of copper or copper bronze powder are added, for instance up to 5% by weight of the diphenyl sulfide. The reaction mixture is advantageously heated at from about 100 to 220 C. for long periods, such as from 4 to 60 hours. Preferably, the reaction mixture is heated with stirring at the boiling point of the solvent for from about 8 to 24 hours. The reaction mixture is worked up by cooling, filtering and quenching in water. The separated product is washed, recrystallized and optionally sublimed to give the desired sulfonylphenothiazine, usually as yellow crystals.
This reaction may be advantageously run in an alternative manner, namely, by alkylating the 2-amino-2'- halo-X-sulfonyldiphenyl sulfide prior to the cyclization thereby substituting the primary amine with a tertiary alkylaminoalkyl moiety which is not reactive under the cyclization conditions subsequently employed. This alltylation is carried out under conditions identical with those described hereafter for the lO-alkylation of the phenothiazinyl trifluoromethyl sulfones. The cyclization conditions of the alkylated amine are identical to those described above. a
The sulfonyldiphenyl sulfidese are prepared by method analogous to those in the prior art, for instance as illustrated hereafter for the preparation of Z-trifluoromethylsulfonylphenothiazine: 1
4 METHOD A son, so,o r,
I --v NO; NO: SE
S030 F; N H
SOQGF N t l --N In Method A, 3-nitro-4-chlorophenyl trifluoromethyl sulfide is oxidized to the corresponding sulfone with chromic anhydride in sulfuric acid. The 3-nitro-4-chlorophenyl trifiuoromethyl sulfone is condensed with obromothiophenol under alkaline conditions to give the diphenyl sulfide. The 2-nitro group is reduced with stannous chloride-hydrochloric acid to give 2-bromo-2-amino-4-trifluoromethylsulfonyldiphenyl sulfide which is then further reacted as described above.
The selected phenothiazinyl trifluoromethyl sulfones of Formula 4 are condensed with a reactive tertiary aminoalkyl ester having the desired dialkylaminoalkyl group to form the desired IO-aminoalkylphenothiazinyl trifluoro-.
methyl sulfone of Formula 1. aminoalkyl ester containing the Any reactive tertiary desired moiety may be used, such as the halides, preferably bromide or chloride, or the sulfonic esters, preferably p-toluene sulfonate. The reaction is preferably carried out at a temperature in the range of from about 30 C. to about C. The condensation is carried out advantageously by refluxing the reactants in an inert aromatic solvent such as, preferably, benzene, toluene or xylene, in which at least one of the reactants must be soluble. A suitable acid-binding agent is usually included, such as an alkali metal amide, preferably, sodium, potassium or lithium amide. Other acid-binding agents are alkali metal hydride, preferably sodium hydride or alkali metal aryl or alkyl compounds, preferably phenyl or actyl sodium. If the acid addition salt of the reactive ester is used, a corresponding increase in acid-binding agent must be used.
The preferred method of alkylation, however, is to react the trifluoromethylsulfonylphenothiazine nucleus with a dialkylarninoalkyl chloride or bromide with a slight excess of sodium or potassium amide in refluxing benzene or toluene for from 30 minutes to 36 hours, preferably 3 to 8 hours.
The preferred method of isolating the IO-aminoalkylphenothiazinyl tr fluommst yl sulfone is to quench the cooled reaction mixtures with an excess of water. The organic layers are extracted with dilute acid, preferably dilute hydrochloric acid. The acid extracts are combined, neutralized and extracted with benzene. The dried benzene extracts are evaporated to give the desired compound, usually as a solid.
The w.-piperazinylalkylphenothiazinyl trifluoromethyl. sulfones are prepared advantageously by alkylating a trifluoromethylsulfonylphenothiazine (Formula 4) with an w-haloalkylpiperazine with the free N-hydrogen of the piperazinyl moiety protected by, for example, a benzyl, carbobenzoxy, or acyl, preferably formyl group. The N- protective group is then removed, such as by mild hydrolysis. The resulting w-piperazinyl alkylphenothiazinylsulfone may then be further alkylated to form various modifications of the compounds of. Formula 1 with optional variations of the moieties of Formula 2. Such methods of alkylation are by a reactive ester such as an alkyl halide in the presence of an acid-binding agent in inert solution such as benzene or butanone, by reaction with an alkylene oxide such as ethylene oxide in alcohol or by reduction of a N-acyl compound such as reduction of the N-acyl analogue with a bimetallic hydride such as lithium aluminum hydride.
Another route to these compounds is by means of w-ester alkylphenothiazinyl trifluoromethyl sulfones which have a reactive end group on the lO-alkyl chain, for example, an w-tosylate or w-chloro end group, which can be reacted with various amines to form primary or secondary amines, for instance by refluxing the ester and amine in the presence of an acid binder for short periods.
The primary IO-(aminoalkyl)-phenothiazinyl trifluoromethyl sulfones are alternatively produced by reacting a trifluoromethylsulfonylphenothiazine of Formula 4 with an excess of acrylonitrile or in an inert solvent such as benzene in the presence of a catalytic amount of strong base, such as a quaternary base, for instance benzyltrimethylammonium hydroxide. The resulting fi-cyanoethyl compound is then reduced, for instance, with lithium aluminum hydride to give the primary amine. Further alkylation of the primary amine gives other compounds of this invention.
The foregoing is a general description of the main synthetic routes in the preparation of lO-(w-aminoalkyD-X- trifluoromethylsulfonylphenothiazine derivatives. It will be readily apparent to one skilled in the art that variations of these procedures arepossible. Of particular advantage as preparative procedures are the methods thoroughly discussed above, especially, N-alkylation of 2-trifluoromethylsulfonylphenothiazine in the -position of the nucleus by a reactive dialkylaminoalkyl ester.
It will be readily apparent to one skilled in the art that certain of the compounds of this invention, notably those in which A is represented by an aliphatic carbon chain branched so that an asymmetric carbon atom is formed or where R and R are alkyl, may be present as optical or cistrans isomers. The connotation of the general formulae presented herein is to include all isomers, particularly the separated d or [optical isomers as well as the dl mixture of these isomers. If desired, the isomers may be'separated for individual use by separation methods known to the art, such as fractional crystallization, for instance, of the d-tartrate salts of the lO-aminoalkylated trifluoromethylsulfonylphenothiazine derivatives. Alternatively, a synthesis starting with an optically active side chain may yield the desired opticalisomer.
The following examples are not limiting but are illustrative of compounds of this invention and the procedures for their preparation and will serve to make fully apparent all of the compounds embraced by the general formula given above and the preparation thereof respectively.
Example 1 A solution of 8.0 g. of chromic anhydride, 8.0 g. of sulfuric acid and 25 ml. of water is mixed with 15.4 g. of
3-nitro-4-chlorophenyl trifluoromethyl sulfide and? the resulting mixture is stirred for 15 hours at -130? C. Steam distilling the reaction mixture yields 3-nitro-4- chlorophenyl trifluoromethyl sulfone.
A solution of 4.0 g. of sodium hydroxide pellets in 30 ml. of water is added to 18.9 g. of Z-bromothiophenol dissolved in 250 ml. of ethanol and the resulting mixture added to a solution of 28.9 g. of 3-nitro-4-chlorophenyl trifluoromethyl sulfone in 100 ml. of ethanol. The suspension is refluxed for three hours. The solid present is filtered from the hot reaction mixture and washed several times with hot ethanol. The combined alcoholic filtrate is diluted with a'small amount'of water and cooled to yield 2-bromo-2-nitro-4-trifluoromethylsulfonyldi phenyl sulfide. i
A solution of 225.7 g. of'stannous chloride crystals in 750 ml. of concentrated hydrochloric acid is carefully mixed with 44.2 g. of2'-bromo-2-nitro-4-trifiuoromethyl sulfonyldiphenyl sulfide. fluxed for five hours. The cooled reaction mixture is filtered and the separated solid metal complex is broken up by hydrolysis for one hour atrefiux with 10% caustic soda and washed with benzene. The organic layer is separated and combined with further benzene washes. The solvent. is then removed by distillation in vacuo and upon purification of the residue, 2'-bromo-2-'amino-4-trifiuoromethylsulfonyldiphenyl sulfide is obtained.
A suspension of 20.6 g. of 2'-bromo-2-amino-4-trifluoromethylsulfonyldiphenyl sulfide, 8.3 g. of anhydrous potassium carbonate and 0.4 g. of copper-bronze powder in 200 ml. of dimethylformamide is stirred and heated at reflux for 18 hours. The cooled reaction mixture is filtered and the filtrate diluted with water. The solid which thus forms is vacuum sublimed at 0.05 mm. (-195 C.) and recrystallized to give pure Z-trifluoromethylsulfonylphenothiazine.
Example 2 A suspension of 33.1 g. of Z-trifluoromethylsulfonylphenothiazine (prepared as in Example 1) and 2.4 g. of lithium amide in 100 ml. of dry toluene is stirred vigorously, slowly heated ot reflux temperature and refluxed for two hours. A solution of 13.3 g. of 3-chloro-l-dimethylaminopropane in 10 ml. of toluene is then added slowly and the resulting mixture refluxed for four hours. After decomposing the excess lithium amide by the cantious addition of 10 ml. of water, the toluene layer is separated and water washed. The dried solvent is removed in vacuo and the residue chromatographed through alumina to give 10-(3'-dimethylaminopropyl) -2-trifluoromethylsulfonylphenothiazine.
A solution of 1.0 g. of the base in 25 ml. of dry ether is treated with ethereal hydrogen chloride yielding the hydrochloride salt.
Example 3 A suspension of 6.6 g. of Z-trifluoromethylsulfonylphenothiazine (made as in Example 1), 1.2 g. of potassium amide and 2.7 g. of Z-chloro-l-dimethylaminopropane in 100 ml. of toluene is heated at reflux for four hours. The reaction mixture is water-washed, extracted With dilute mineral acid and acidic extracts neutralized with aqueous ammonia. Upon benzene extraction, the residual basic oil is reacted with bismethylenesalicyclic acid in ethyl acetate solution. to give, after purification, 10 (dimethylaminoisopropyl) 2 trifluoromethylsulfonylphenothiazine bismethylenesalicylate.
Example 4 A mixture of 16.5 g. of Z-trifluoromethylsulfonyh phenothiazine (made as in Example 1), 2.4 g. of sodamide and 10.5 g. of 1-(3-chloropropyl)-4-methylpiperazine in 200 ml. of xylene is stirred and refluxed for four hours. The reaction mixture is extracted with water and the separated xylene layer extracted portion-wise with dilute hydrochloric acid. The combined acid extracts are The mixture is stirred and re- 7 neutralized with ammonium hydroxide and the product taken up in benzene. Removal of the solvent and chromatography over alumina yields 10-[3'-(4-methy1-1"- piperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine. Treating the oil with maleic acid in ethyl acetate results in theformation of the dimaleate salt.
Example 5 A suspension of 66.2 g. of Z-trifluoromethylsulfonylphenothiazine (made as in Example 1) and 8.2 g. of sodium amide in 900 m1. of toluene is heated at reflux with rapid stirring for 15 minutes. A solution of 41.8 g. of l-formyl-4-(3'-chloropropyl)-piperazine in 100 ml. of toluene is added and refluxing continued for six hours. The cooled reaction mixture is treated with 150 ml. of water and toluene layer extracted with dilute hydrochloric acid. The acid extracts are made basic with ammonia and extracted with benzene. The solvent is distilled ofl in vacuo, leaving the residual -[3'-(N-formylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine as a viscous oil.
Example 6 Example 7 A stirred suspension of 22.8 g. of 10-(3'-piperazinylpropyl) -2-trifluoromethylsulfonylphenothiazine (prepared as in Example 6), 8.9 g. of B-bromoethyl acetate and 3.6 g. of potassium carbonate in 200 m1. of toluene is refluxed for 16 hours; The cooled reaction mixture is treated with water and the separated organic layer extracted with dilute acid. The combined acid extract is neutralized, further extracted with benzene and upon evaporation of the solvent in vacuo, an oily residue is obtained which is purified by chromatography through alumina. A solution of the free base in ether is treated with ethereal hydrogen chloride to give l0-[3(N-acetoxyethylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine dihydrochloride.
Example 8 A solution of 2.2 g. of l0-[3'-(N-acetoxyethylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine (prepared as in Example 7) in 50 ml. of l N hydrochloric acid is refluxed for a short time. The reaction mixture is neutralized with dilute sodium carbonate solution and extracted with benzene. Evaporation of the solvent gives 10-[3(N-B-hydroxyethylpiperazinyl)-propyl]-2-trifiuoromethylsulfonylphenothiazine as an oil.
Example 9 azinyl) -propyl]-2-trifluoromethylsulfonylphenothiazine.
for four hours.
Example 10 To a solution of 4.6 g. of l0-(3'-piperazinylpropyl)-2- trifiuoromethylsulfonylphenothiazine (made as in Example 6) in 150.0 g. of benzene, 1.8 g. of phenylacetyl chloride is added dropwise with swirling. The mixture, after standing overnight, is filtered to give crystals of 10-[3' (N phenylacetylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine hydrochloride.
Example 11 A suspension of 9.2 g. of 10-(3-piperazinylpropyl)-2- trifluoromethylsulfonylphenothiazine, 5.6 g. of 4-bromo- 4'-hydroxybutyl ether (prepared by carefully treating 4,4-dihydroxybutyl ether with one equivalent of hydrobromic acid) and 4.2 g. of potassium carbonate in 200 ml. of xylene is heated at reflux for 24 hours. After treating the reaction mixture with water, the separated organic layer is extracted with acid. The acidic extracts are made basic and extracted with benzene. Removal of the solvent from the dried extracts yields l0-[3-(N-hydroxybutoxybutylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine.
Example 12 A stirred suspension of 16.5 g. of 2-trifluoromethylsulfonylphenothiazine and 3.9 g. of sodamide in 150 ml. of xylene is refluxed while 13.6 g. of 3-bromo-1-pyrrolidinylpropane hydrobrornide is added portion-wise. After the addition is complete, stirring and heating is continued for 15 hours. The cooled reaction mixture is carefully treated with ice water. The separated organic layer combined with several benzene washes is extracted with dilute hydrochloric acid. The acid extracts are neutralized with sodium hydroxide solution and then ether extracted. Evaporation of the ether gives l0-(3'-N-pyrrolidinylpropyl) -2-trifluoromethylsulfonylphenothiazine.
A solution of the base in ether is treated with glacial acetic acid to give the acetate salt.
Example 13 A mixture of 9.2 g. of l0-(3-piperazinylpropyl)-2-trifiuoromethylsulfonylphenothiazine, 1.8 g. of crotyl chloride and 1.6 g. of potassium carbonate in ml. of aqueous ethanol is stirred and heated at reflux for six hours. The reaction mixture is worked up as outlined in Example 7 to give lO-[3-(N-crotylpiperazinyl)-propyl]2-trifiuoromethylsulfonylphenothiazine.
Similarly, using cinnamyl chloride as described above, 10 [3 (N cinnamylpiperazin-yl) propyl] 2 trifiuoromethylsulfonylphenothiazine is obtained.
Example 14 A suspension of 33.1 g. of Z-trifluoromethylsulfonylphenothiazine (prepared as in Example 1) and 2.4 g. of lithium amide in 100 ml. of dry toluene is refluxed for two hours. A solution of 14.9 g. of 2-chloro-l-diethylaminoethane in 25 ml. of toulene is added slowly and the resulting mixture refluxed for four hours. The excess lithium amide is decomposed by the addition of 20 ml. of water. The toluene layer is separated and washed with water. The dried solvent is removed in vacuo to yield crude l0-(2-diethylaminoethyl)-2-trifiuoromethylsulfonylphenothiazine.
A solution of 1.0 g. of the base in 25 ml. of dry other is treated with excess ethereal hydrogen chloride to give the hydrochloride salt.
Example 15 A suspension of 16.5 g. of Z-trifiuoromethylsulfonylphenothiazine (prepared as in Example 1), 16.2 g. of N carbobenzoxy N (a chloro 3 methylpropyl)- piperazine (prepared from the reaction of N-ca-rbobenzoxypiperazine with 3-bromo-2-methylpropyl chloride) and 2.2 g. of sodamide in 250 m1. of toluene is refluxed The reaction mixture is treated with 9 Water and the organic layer is separated and washed with water. The dried solvent is removed in vacuo to yield 10 [3 (N carbobenzoxypiperazinyl) 2' methylpropyl] -2-trifluorom ethylsulfonylphenothiazine.
A solution of 18.0 g. of 10-[3-(N-carbobenzoxypiperazinyl) 2 methylpropyl] 2 trifluoromethylsulfonylphenothiazine in 200 ml. of aqueous ethanol and 10 ml. of 40% sodium hydroxide solution is refluxed for four hours. After removal of the alcohol in vacuo, the residue is treated with benzene and Water. The dried benzene layer is evaporated to give the product 10-(2'-methy1-3'- piperazinylpropyl) 2 trifluoromethylsulfonylphenothiazme.
A solution of the free base (1.0 g.) in ethyl acetate is treated with a solution of mandelic acid in ethanol. Concentration and cooling of the resulting solution yields the dimandelate salt.
Example 16 A mixture of 14.1 g. of 10-(2'-methyl-3'-piperazinylpropyl) -2-trifluoromethylsulfonylphenothiazine' (prepared as in Example and 60 ml. of 85% formic acid solution is warmed to 50 C., after which ml. of 37% formalin solution is added slowly. The temperature of the reaction mixture is maintained at 50 to 60 C. until there is no further evolution of carbon monoxide. The mixture is neutralized with dilute sodium hydroxide solution and extracted With benzene. Removal of the dried solvent and vacuum distillation of the residue gives 10- [3' (4" methyl 1 piperazinyl) 2' methylpropyll- 2-trifluoromethylsulfonylphenothiazine.
A solution of 1.0 g. of the free base in ml. of dry ether is treated with an excess of ethereal hydrogen chloride to give the dihydrochloride salt.
Example 17 To a stirred suspension of 19.2 g. of 10-(2-cyanoethyl)-2-trifiuoromethylsulfonylphenothiazine (prepared from the reaction of 2-trifluoromethylsulfonylphenothiazine, which is prepared as in Example 1', and acrylonitrile with benzyltrimethylammonium hydroxide) in 700 ml. of dry ether, a solution of 8.0 g. of lithium aluminum hydride in 250 m1. of ether is added slowly. The mixture is refluxed for eight hours, cooled and treated with methanol to destroy the metal complex. After filtration, the filtrate is evaporated and the residue extracted several times with dilute hydrochloric acid. The acidic extracts are neutralized and extracted with chloroform. Evaporation of the solvent yields 10-(3'-aminopropyl)- 2-trifluoromethylsulfonylphenothiazine.
Example 18 A mixture of 16.3 g. of 10-(3'-hydroxypropyl)-2-trifluoromethylsulfonylphenothiazine p-toluene sulfonate (prepared by condensing the sodio derivative of 2-trifluoromethylsulfonylphenothiazine with bromopropyltetrahydropyranyl ether, hydrolyzing the protective pyranyl group with hydrochloric acid and acylating the resulting 'y-hydroxy compound with excess p-toluenesulfonyl chloride in pyridine) and 9.0 g. of butylamine in 75 ml. of ethanol is refluxed for ten hours. The reaction mixture is evaporated on the steam bathand the residue extracted with a water-chloroform mixture. The organic layer is separated and extracted with dilute hydrochloric acid. The acid extracts are neutralized with sodium carbonate solution and extracted with ethyl acetate. Treating the ethyl acetate solution with maleic acid results in the formation of 10-(3'-butylaminopropyl)- Z-tn'fiuoromethylsulfonylphenothiazine maleate.
Example 19 A suspension of 33.1 g. of 2-trifluoromethylsulfonylphenothiazine (prepared as in Example 1) and 2.4 g. of lithium amide in 125 ml. of xylene is mixed slowly with a solution of 22.7 g. of 3-bromo-1-piperidylpropane in ml. of' xylene at 100 C. The mixture is then refluxed for four hours, cooled and treated with water. The organic layer is extracted with acid and the acid extracts are neutralized with ammonium hydroxide solution. The resulting solution is extracted with benzene; the solvent is then removed by distillation in vacuo to give the product, 10-(3'-N-piperidylpropyl)-2-trifluoromethylsulfonylphenothiazine.
Example 20 A suspension of 6.6 g. of Z-trifluoromethylsulfonylphenothiazine (prepared as in Example 1), 0.8 g. of sodamide and 5.1 g. of 3-chloro-1-(1,2',3',5',6'-pentamethylpiperazinyD-propane-in 150 ml. of toluene is refluxed for four hours. The reaction mixture is treated with water and the organic layer extracted several times with dilute hydrochloric acid. The acid extracts are neutralized with ammonium hydroxide solution and extracted with benzene. The solvent. is removed yielding the product, 10- [3' (1",2,3",5,6" pentamethylpiperazinyl) pro pyl] -2-trifluoromethylsulfonylph eno thiazine.
By treating 1.0 g. of the. free base with excess maleic acid in ethyl acetate solution, the dimaleate'salt is obtained.
Example 21 A mixture of 6.6 g. of 2-trifluoromethylsulfonylphenothiazine (made as in Example 1), 0.8 g. of sodamide and 5.1 g. of 3-chloro-1-(1'-methyl-2,5-diethylpiperazinyl)- propane in 250 ml. of toluene is refluxed for four hours. Working up the mixture as described in Example 20 yields the product, 10-[3- l"-methyl-2",5"-diethylpiperazinyl)- propyl] -2-trifluoromethylsulfonylphenothiazine.
Example 22 A mixture of 19.4 g. of 10-(3'-aminopropyl)-2-trifluoro methylsulfonylphenothiazine (made as in Example 17) and 10.9 g. of butyl bis-(,B-chloroethyD-amine in 150 ml. of butanol is refluxed for nine hours. T ributylarnine (20 ml.) is added and the refluxing continued for eight hours. The reaction mixture is concentrated by heating on the steam bath under reduced pressure, diluted with water and extracted with chloroform. The extracts are evaporated to yield the residue, 10-[3'-(4-butyl-1"-piperazinyl)-propyl] -2-trifluoromethylsulfonylphenothiazine.
A solution of the free base (1.0 g.) in 50 ml. of acetone is reacted with an excess of citric acid in acetone to give the dicitrate salt.
Example 23 A suspension of 9.1 g. of 10 (3-piperazinylpropyl)-2- tr'ifiuoromethylsulfonylphenothiazine (made as in Example 6), 0.8 g. of sodium amide and 3.3 g. of 2-bromo-ldimethylaminoethane in ml. of benzene is refluxed for six hours, With stirring. Treating the reaction mixture as in Example 20 gives the product, 10-[3-(N- 3-dimethylaminoethylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine.
Example 24 A stirred suspension of 9.1 g. of l0-(3'-piperazinylpropyl)-2-trifluoromethylsulfonylphenothiazine *(made as in Example 6), 3.4 g. of w-bromobutanol and 4.0 g. of potassium carbonate in 125 ml. of xylene is refluxed for six hours. Water is added to the reaction mixture and the separated xylene layer is extracted with dilute hydrochloric acid. The acid extracts are neutralized and extracted with benzene. The solvent is distilled in vacuo to give a residue of 10-[3'-(N-w-hydroxybutylpiperazinyl)- propyl] -2'-trifluoromethylsulfonylphenothiazine.
A mixture of 5.3 g. of the free base in 100 ml. of henzene and 3.6 g. of butyryl chloride is allowed to stand at room temperature for 12 hours. The reaction mixture is poured into water, neutralized and extracted with benzene. The residue upon-evaporation of solvent is the crude product, 10-[3'-(N-w-butyryloxybutylpiperazinyl)- propyl] -2-trifluoromethylsulfonylphenothiazine.
Example 25 A mixture of 10.8 g. of 10-(3'-hydroxypropyl)-2-trifiuoromethylsulfonylphenothiazine p toluenesulfonate (prepared as outlined in Example 18), 5.0 g. of N- hydroxyethoxyethylpiperazine and 4.2 g. of potassium carbonate in 150 ml. of ethanol is heated at reflux for six hours, with stirring. The reaction mixture is treated with water, evaporated in vacuo and extracted with ethyl acetate. Evaporation of the dried solvent yields the product, 10 [3' (N hydroxyethoxyethylpiperazinyl) propyl] 2-trifluoromethylsulfonylphenothiazine.
Example 26 A suspension of 33.1 g. of Z-trifiuoromethylsulfonylphenothiazine (prepared as in Example 1), 4.1 g. of sodamide and 29.3 g. of 3-chloro-1-(N-phenethylpiperazinyl) propane in 500 m1. of toluene is refluxed for eight hours. Working up as in Example 20, the dimaleate salt of 10- 3'- (N-phenethylpiperazinyl) -propyl] -2-trifluor0- methylsulfonylphenothiazine is obtained.
Example 27 To a stirred mixture of 9.1 g. of 10"(3'-piperazinylpropyl)-2-trifluoromethylsulfonylphenothiazine (made as in Example 6), dissolved in 500 ml. of benzeneand 10 ml. of pyridine is added 6.0 g. of acetic anhydride. The resulting mixture is allowed to stand for 16 hours, washed with water and evaporated to dryness. The residue is dissolved in alcohol and reacted with one equivalent of hydrochloric acid to give 10-[3-(N-acetylpiperazinyl)- propyl] 2 trifluoromethylsulfonylphenothiazine hydrochloride.
Example 28 A mixture of 9.1 g. of l-(3'-piperazinylpropyl)-2-trifluoromethylsulfonylphenothiazine (made as in Example 6) and 9.4 g. of benzoyl chloride in 300 ml. of benzene is refluxed for eight hours. Concentration of the reaction mixture yields -[3'-(N-benzoylpiperazinyl)-propyl]-2 trifiuoromethylsulfonylphenothiazine hydrochloride.
Example 29 SO50 F,
10 9 N r 2 .l z
in which Z is a member selected from the group consisting of amino, monoalkylamino, dialkylamino, pyrrolidinyl, piperidinyl, piperazinyl, N-alkylpiperazinyl, N-(w-hydroxyalkylene)-piperazinyl, N-(waikanoyloxyalkylene)- piperazinyl, N-(w-benzoyloxyalkylene)-piperazinyl, N-(wdialkylaminoalkylene)-piperazinyl, N-(w-hydroxy alkyleneoxy-alkylene)-piperazinyl, N-cinnamylpiperazinyl, N- phenethylpiperazinyl, N-alkanoylpiperazinyl, N-phenylalkanoylpiperazinyl, N-benzoylpiperazinyl, N-carbobenzoxypiperazinyl, N-dialkyl carbamylpiperazinyl, N, 2,3,5,6-
pentamethylpiperazinyl and N-methyl-Z,S-diethylpiperazinyl; and A is an alkylene chain having 2 to 6 carbon atoms and separating the nitrogens to which it is attached by at least 2 carbon atoms; each of the said alkyl moieties having 1 to 6 carbon atoms and each of the said alkylene and alkanoyl moieties having 2 to 6 carbon atoms.
2. A chemical compound having the basic structural formula:
S g @S 020 Fa CHz-GHr-G Hr-N 3. A chemical compound having the basic structural formula:
4. A chemical compound having the basic structural formula:
(IN/@8020 F; l
in which A is an alkylene chain having 2 to 6 carbon atoms andseparating the nitrogens to which it is attached by at least 2 carbon atoms; and R; is alkyl having to 1 to 6 carbon atoms.
5. A chemical compound having the basic structural formula:
SOICF3 N iilHr-CHrCHg-N N-CH;
6. A chemical compound having the basic structural formula:
HrCH-CHz-N N-CH3 7. A chemical compound having the basic structural formula:
in which A is an alkylene chain having 2 to 6 carbon atoms and separating the nitrogens to which it is attached by at least 2 carbon atoms; and R is w-hydroxyalkylene having 2 to 6 carbon atoms.
13 14 8. A chemical compound having the basic structural in which A is an alkylene chainhaving 2 to 6 carbon formula: atoms and separating the nitrogens to which it is attached 8 by at least 2 carbon atoms; and R is w-alkanoyloxyalkylene, the alkanoyl and alkylene moieties each having 2 to 5 6 carbon atoms.
N S02 10. A chemical compound having the basic structural formula:
Hz-OHg-CHr-N N-CHg-CHz-OH S 9. A chemical compound having the basic structural 10 formula: \N 8 0,0
CH 0 CH Hr-CHg-CHz-N N r- Hz-O l N SOQGF; 15
No references cited. l m

Claims (1)

1. A CHEMICAL COMPOUND OF THE CLASS CONSISTING OF A FREE BASE AND ITS NONTOXIC ACID ADDITION SALTS, THE FREE BASE HAVING THE FORMULA:
US728773A 1957-06-10 1958-04-16 Substituted phenothiazinyl trifluoro-methyl sulfones Expired - Lifetime US2914528A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BE568478D BE568478A (en) 1957-06-10
US728773A US2914528A (en) 1958-04-16 1958-04-16 Substituted phenothiazinyl trifluoro-methyl sulfones
GB17724/58A GB851886A (en) 1957-06-10 1958-06-03 Substituted phenothiazinyl trifluoromethyl sulfones
GB2640/60A GB851887A (en) 1957-06-10 1958-06-03 Substituted phenothiazinyl trifluoromethyl sulfones
DES58547A DE1173099B (en) 1957-06-10 1958-06-09 Process for the preparation of trifluoromethylsulfonyl-phenthiazines with basic substitution in the 10-position
FR767619A FR1245551A (en) 1957-06-10 1958-06-10 Process for the preparation of substituted thiazinyl trifluoromethyl sulfones
US803090A US2919272A (en) 1957-06-10 1959-03-31 Substituted phenothiazinyl trifluoromethyl sulfones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US728773A US2914528A (en) 1958-04-16 1958-04-16 Substituted phenothiazinyl trifluoro-methyl sulfones

Publications (1)

Publication Number Publication Date
US2914528A true US2914528A (en) 1959-11-24

Family

ID=24928225

Family Applications (1)

Application Number Title Priority Date Filing Date
US728773A Expired - Lifetime US2914528A (en) 1957-06-10 1958-04-16 Substituted phenothiazinyl trifluoro-methyl sulfones

Country Status (1)

Country Link
US (1) US2914528A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3000886A (en) * 1958-10-06 1961-09-19 Smith Kline French Lab Substituted aroylalkyl phenothiazinylalkyl piperazines
US3133917A (en) * 1964-05-19 Substituted trifluoromethoxy- and tri-
US3189657A (en) * 1960-11-03 1965-06-15 Lilly Co Eli 5-(3-bromopropylidene) dibenzo-[a, d] cyclohepta (1.4)diene
US20040242570A1 (en) * 2001-09-27 2004-12-02 Abraham Nudelman Conjugated psychotropic drugs and uses thereof
US20090298814A1 (en) * 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
US20090304584A1 (en) * 2006-07-17 2009-12-10 Ramot At Tel Aviv University Ltd. Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
US20110034553A1 (en) * 2008-02-11 2011-02-10 Ramot At Tel-Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
US20110178073A1 (en) * 2009-12-09 2011-07-21 Geffen Yona Methods of improving cognitive functions
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133917A (en) * 1964-05-19 Substituted trifluoromethoxy- and tri-
US3000886A (en) * 1958-10-06 1961-09-19 Smith Kline French Lab Substituted aroylalkyl phenothiazinylalkyl piperazines
US3189657A (en) * 1960-11-03 1965-06-15 Lilly Co Eli 5-(3-bromopropylidene) dibenzo-[a, d] cyclohepta (1.4)diene
US20100204469A1 (en) * 2001-09-27 2010-08-12 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US7939525B2 (en) 2001-09-27 2011-05-10 Bar-Ilan University Conjugated psychotropic drugs and uses thereof
US7598239B2 (en) * 2001-09-27 2009-10-06 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US7619006B2 (en) * 2001-09-27 2009-11-17 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US8283381B2 (en) 2001-09-27 2012-10-09 Ramot At Tel-Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US8168628B2 (en) 2001-09-27 2012-05-01 Ramot At Tel-Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20100063034A1 (en) * 2001-09-27 2010-03-11 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20100120755A1 (en) * 2001-09-27 2010-05-13 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040242570A1 (en) * 2001-09-27 2004-12-02 Abraham Nudelman Conjugated psychotropic drugs and uses thereof
US20090298814A1 (en) * 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
US20100144869A1 (en) * 2006-07-17 2010-06-10 Abraham Nudelman Conjugates Comprising a gaba-or glycine compound, pharmaceutical compositions and combinations thereof as well as their use in treating cns disorders
US20090304584A1 (en) * 2006-07-17 2009-12-10 Ramot At Tel Aviv University Ltd. Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
US8222296B2 (en) 2006-07-17 2012-07-17 Ramot At Tel-Aviv University Ltd. Conjugates comprising a GABA- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disorders
US8377990B2 (en) 2006-07-17 2013-02-19 Ramot At Tel-Aviv University Ltd. Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
US20110034553A1 (en) * 2008-02-11 2011-02-10 Ramot At Tel-Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
US8722923B2 (en) 2008-02-11 2014-05-13 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
US20110178073A1 (en) * 2009-12-09 2011-07-21 Geffen Yona Methods of improving cognitive functions
US8975251B2 (en) 2009-12-09 2015-03-10 Bar-Ilan University Methods of improving cognitive functions
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same

Similar Documents

Publication Publication Date Title
US2921069A (en) Substituted trifluroromethylpheno-thiazine derivatives
US3058979A (en) New perfluoroalkylphenothiazine derivatives
US4062848A (en) Tetracyclic compounds
US2914528A (en) Substituted phenothiazinyl trifluoro-methyl sulfones
US3074931A (en) Dibenzazepines
US3192204A (en) Trifluoromethylthiaxanthene and -xanthene derivatives
US2877224A (en) 3-cyano substituted phenothiazines
HU191301B (en) Process for preparing 1-/hydroxy-methyl/-1,6,7,11b-tetrahydro-2h,4h-/1,3/-oxazino- or -thiazino/4,3-a/isoquinoline -derivatives
US2889322A (en) 3-methanesulphonyl phenthiazine derivatives
US2919272A (en) Substituted phenothiazinyl trifluoromethyl sulfones
DE1695132A1 (en) Process for the preparation of heterocyclic compounds
US2956996A (en) Alkylated phenotfflazenecarboxamede
US3647800A (en) 10-substituted - 1 2 3 4 - tetrahydrobenzo(b)(1 6)naphthyridines useful as cns depressants
US3068222A (en) Trifluoromethyl substituted dibenzxze-
CA1177830A (en) Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
NL8002610A (en) HETEROCYCLIC COMPOUNDS AND METHODS FOR PREPARING AND USING THESE COMPOUNDS.
US3637706A (en) 10-(4 - (lower)alkylpiperazino) - 1 2 3 4-tetrahydrobenzo(b)(1 6) naphthyridine derivatives useful as cns depressants
US2944054A (en) Substituted phenothiazinylalkyl aminosulfonylpiperazines
US3470168A (en) 2-substituted-4h-1,3-benzothiazin-4-one derivatives
US3481921A (en) Benzodiazepines
US3574204A (en) Piperidine spiro compounds
US2979502A (en) Phenthiazine derivatives
US2944053A (en) Uiiilcu
US3000886A (en) Substituted aroylalkyl phenothiazinylalkyl piperazines
US2894947A (en) Phenthiazine derivatives